Literature DB >> 28202168

Paraprotein-associated thrombotic microangiopathy: expanding the spectrum of renal disease related to plasma cell dyscrasias.

Mercury Lin1, Mark Haas2.   

Abstract

Plasma cell dyscrasias are associated with a variety of renal diseases, most resulting from the deposition of intact or altered monoclonal paraproteins within the renal parenchyma. Much less commonly, renal disease resulting from monoclonal gammopathies has been reported without actual accumulation of the paraprotein or a derivative of it within the kidney. One such instance involves thrombotic microangiopathy (TMA), which is a consequence of endothelial cell injury. New data from the Mayo Clinic indicate that the association of TMA with monoclonal gammopathies is far more frequent than previously appreciated. These findings have potentially important implications for the treatment of TMA in a significant number of patients.
Copyright © 2017 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28202168     DOI: 10.1016/j.kint.2016.10.043

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  3 in total

Review 1.  Pathophysiology and management of monoclonal gammopathy of renal significance.

Authors:  Ankur Jain; Richard Haynes; Jaimal Kothari; Akhil Khera; Maria Soares; Karthik Ramasamy
Journal:  Blood Adv       Date:  2019-08-13

2.  Thrombotic microangiopathy with intraglomerular IgM pseudothrombi in Waldenström macroglobulinemia and IgM monoclonal gammopathy.

Authors:  Serena Yen Shan Tan; Richard Kent Sibley; Sharina Belani; Sumie Iwasaki; Leonid Yankulin; Tracy Jonelis; John Patrick Twistington Higgins; Neeraja Kambham; Megan Leigh Troxell
Journal:  J Nephrol       Date:  2018-10-17       Impact factor: 3.902

3.  Clinicopathological features and individualized treatment of kidney involvement in B-cell lymphoproliferative disorder.

Authors:  Guangyan Nie; Lianqin Sun; Chengning Zhang; Yanggang Yuan; Huijuan Mao; Zhen Wang; Jianyong Li; Suyan Duan; Changying Xing; Bo Zhang
Journal:  Front Immunol       Date:  2022-09-12       Impact factor: 8.786

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.